Larimar Therapeutics Inc

+0.06 (+1.97%)
Earnings Announcements

Larimar Therapeutics Reports Q3 2022 Results

Published: 11/10/2022 12:47 GMT
Larimar Therapeutics Inc (LRMR) - Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results.
Larimar Therapeutics - Expects to Provide an Update on Phase 2 Trial in Q2 2023 and Anticipates Reporting Top-line Data From Both Cohorts in 2h 2023.
Cash of $124.7 Million at September 30, 2022 Provides Projected Cash Runway Into 2h 2024.
Qtrly Loss per Share $0.37.
Q3 Earnings per Share View $-0.42 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.42

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.